NEW YORK, April 20, 2016 /PRNewswire-USNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today Mark Fischer-Colbrie has been elected as the new chairman of the JDRF International Board of Directors ("IBOD"). Mr. Fischer-Colbrie will succeed JDRF IBOD Chairman John Brady, whose two-year term ends June 30.
"It's an honor to pass the title and duties of Chairman of the International Board to Mark Fischer-Colbrie," said JDRF IBOD Chairman John Brady. "Mark has a broad and unique skill set, with deep knowledge and proven success in life sciences research and commercialization, as well as an exemplary track record in the management and oversight of innovative, high-growth businesses. In addition, Mark has demonstrated effective leadership within JDRF at both the chapter and national levels," Mr. Brady added. "As a three-time chapter president, he understands that our chapters are the heart and soul of JDRF. There's no one more qualified to lead our IBOD at this time, and JDRF and the entire type 1 diabetes community are lucky to have such a passionate supporter to lead our fight against this disease."
Mark Fischer-Colbrie became involved with JDRF in 2000 after his son was diagnosed with type 1 diabetes. He and his entire family have been committed to JDRF for many years. His tenure includes JDRF International Board of Directors Member, Executive Committee Member, Finance Chairman, Research, Nominating and Governance, and Long Range Planning Committee Member. Mr. Fischer-Colbrie has been extremely active in the JDRF Greater Bay Area Chapter, where he has served as President for three terms, Vice President of Research, Vice President of Corporate Development and Vice President of Government Relations. In 2000, Mr. Fischer-Colbrie co-founded the JDRF Silicon Valley Chapter.
Mr. Fischer-Colbrie is currently the President and CEO of Labcyte Inc., where he has worked since 2007. He has 25 years of experience in the biomedical field, and has a deep understanding of science, research, drug discovery and medical devices. Over the years, Mr. Fischer-Colbrie has raised more than $500 million in private and public capital, and has been broadly involved in every aspect of a company's operations, including research and development. He is the author of three biomedical patents.
"As a fellow parent of a child with type 1 diabetes, I am extremely confident that Mark will lead the Board and provide true inspiration for everyone affected by this disease," said Derek Rapp, JDRF President and CEO. "Few people have been as actively and broadly engaged in JDRF as Mark, and I'm very pleased he will be taking the reins to continue our mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. I also want to sincerely thank John Brady for his years of service, his tremendous passion, and his unmatched dedication to the Board and the entire JDRF family. We greatly appreciate his insight and leadership as chairman over the last two years."
"I am honored to be elected as the new IBOD Chairman and look forward to working closely with Derek and the IBOD," said Mark Fischer-Colbrie. "I am eager to build on the strong groundwork John Brady created, and I know my previous work with the JDRF business development team and other key groups to progress JDRF research will be important as we continue our vision for a world without type 1 diabetes."
Mr. Fischer-Colbrie has been honored and awarded for his achievements in both the business and non-profit world. In 2013, he was named National Finalist Life Sciences for the Ernst & Young National Entrepreneur of the Year. In 2015, Fischer-Colbrie was awarded the JDRF Impact Award by the Greater Bay Area.
Mr. Fischer-Colbrie will assume the position of Chairman of the JDRF IBOD starting July 1, 2016.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers in more than 100 locations throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.